IP Library Granted Patent US 12667561
Granted Patent B2
US 12667561 · App. 18/458,390 · Granted Jun 30, 2026

Gel containing pirfenidone

Inventors: José Agustín Rogelio Magaña Castro (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX); Juan Socorro Armendáriz Borunda (Mexico City, MX)
Assignee: Excalibur Pharmaceuticals, Inc.
A61K31/4418A61K9/0014A61K9/06A61K47/02A61K47/18A61K47/22A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667561
App. No.
18/458,390
Granted
Jun 30, 2026
Kind
B2
Abstract

The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.

Claims (21)

1 . A composition of pirfenidone gel consisting of:

(i) 2-12% pirfenidone;

(ii) 0.4-1.2% of Carbomer 940®;

(iii) 10-30% of N-methylpyrrolidone;

(iv) 5-15% of macrogolglycerol hydroxystearate 40;

(v) 0.2-1% of diazolidinyl urea and iodopropynyl butylcarbamate;

(vi) 0.4-1.2% of triethanolamine; and

(vii) water.

2 . The composition of claim 1 , wherein the composition consists of 8% pirfenidone, 0.5% of Carbomer 940®, 20% of N-methylpyrrolidone, 11.5% of macrogolglycerol hydroxystearate 40, 0.5% of diazolidinyl urea and iodopropynyl butylcarbamate, 0.5% of triethanolamine, and 59% of water.

3 . The composition of claim 1 , wherein the composition is an anti-fibrotic composition.

4 . The composition of claim 1 , wherein the composition is an anti-inflammatory composition.

5 . The composition of claim 1 , wherein the composition consists of:

(i) 8% pirfenidone;

(ii) 0.5% of Carbomer 940®;

(iii) 10-30% of N-methylpyrrolidone;

(iv) 5-15% of macrogolglycerol hydroxystearate 40;

(v) 0.5% of diazolidinyl urea and iodopropynyl butylcarbamate;

(vi) 0.5% of triethanolamine; and

(vii) water.

6 . The composition of claim 5 , wherein the composition is an anti-fibrotic composition.

7 . The composition of claim 5 , wherein the composition is an anti-inflammatory composition.